Nadia Harbeck

Research interests

Publications

• Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.11.016

• Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203690

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019

• Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.05.801

• Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

  The Lancet · 2020 · 10.1016/s0140-6736(20)31953-x

• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.09.010

• Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

  Journal of Clinical Oncology · 2020 · 10.1200/jco.20.02514

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32531-9

• Pembrolizumab for Early Triple-Negative Breast Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1910549

• Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1903765

• Breast cancer

  Nature Reviews Disease Primers · 2019 · https://doi.org/10.1038/s41572-019-0111-2

• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1810527

• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)

  Annals of Oncology · 2018 · 10.1093/annonc/mdy192

• Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30292-4

• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  Annals of Oncology · 2017 · 10.1093/annonc/mdx308

• Palbociclib and Letrozole in Advanced Breast Cancer

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1607303

• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet Oncology · 2016 · 10.1016/s1470-2045(15)00613-0

• Breast cancer

  The Lancet · 2016 · https://doi.org/10.1016/s0140-6736(16)31891-8

• 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

  Annals of Oncology · 2016 · 10.1093/annonc/mdw544

• Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505270

• Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2008.21.6457

• Triple-negative breast cancer—current status and future directions

  Annals of Oncology · 2009 · 10.1093/annonc/mdp492

• National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

  Clinical Chemistry · 2008 · 10.1373/clinchem.2008.105601

• 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

  The Lancet · 2007 · 10.1016/s0140-6736(07)60028-2

• Pooled Analysis of Prognostic Impact of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in 8377 Breast Cancer Patients

  JNCI Journal of the National Cancer Institute · 2002 · 10.1093/jnci/94.2.116

Current projects

No projects listed.